Cancer cannot be understood as a single, uniform disease. The more we delve into studying each type of tumor, the more we recognize the need to subclassify the disease. This concept has led to what we ...

CIC bioGUNE leads a study showing that multi-omic data can identify silent and stable risk profiles in healthy individuals The study, conducted using local cohorts from the Basque Country, ...

NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced new insights that highlighted the frustrations many patients with chronic idiopathic constipation (CIC) feel with ...

VectivBio Holding AG (VectivBio), a clinical-stage biopharmaceutical company, announced the completion of enrollment of the Colon-in-Continuity (CIC) cohort for the company’s phase 3 STARS (STudy of ...

Synergy announced additional clinical data from two Phase 3 trials, Study-00 and Study-03, evaluating the efficacy and safety of plecanatide for the treatment of chronic idiopathic constipation (CIC).